UY26341A1 - METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES. - Google Patents
METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES.Info
- Publication number
- UY26341A1 UY26341A1 UY26341A UY26341A UY26341A1 UY 26341 A1 UY26341 A1 UY 26341A1 UY 26341 A UY26341 A UY 26341A UY 26341 A UY26341 A UY 26341A UY 26341 A1 UY26341 A1 UY 26341A1
- Authority
- UY
- Uruguay
- Prior art keywords
- diabetes
- treatment
- metabolic disorders
- disease
- condition associated
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 229960000698 nateglinide Drugs 0.000 abstract 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960002354 repaglinide Drugs 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a una combinación, tal como una preparación combinada o una composición farmacéutica, su uso y preparación respectivamente, que comprende nateglinida (I) o repaglinida, y cuando menos otro compuesto antidiabético seleccionado a partir del grupo que consiste en derivados de tiazolidinadiona (glitazonas), derivados de sulfonilurea, y metformina, para el uso simultáneo, separado, o en secuencia, en la prevención, demora de progreso, o tratamiento de enfermedades, especialmente desórdenes metabólicos, y en particular diabetes tipo 2, y enfermedades y condiciones asociadas con diabetes.The invention relates to a combination, such as a combined preparation or a pharmaceutical composition, its use and preparation respectively, comprising nateglinide (I) or repaglinide, and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), derivatives of sulfonylurea, and metformin, for simultaneous, separate, or sequential use, in the prevention, delay of progress, or treatment of diseases, especially metabolic disorders, and in particular type 2 diabetes, and diseases and conditions associated with diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY26341A UY26341A1 (en) | 2000-09-15 | 2000-09-15 | METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY26341A UY26341A1 (en) | 2000-09-15 | 2000-09-15 | METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26341A1 true UY26341A1 (en) | 2001-04-30 |
Family
ID=38812220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26341A UY26341A1 (en) | 2000-09-15 | 2000-09-15 | METHOD FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES. |
Country Status (1)
| Country | Link |
|---|---|
| UY (1) | UY26341A1 (en) |
-
2000
- 2000-09-15 UY UY26341A patent/UY26341A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037407A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS TYPE II DIABETES | |
| CO5200844A1 (en) | A COMBINATION THAT INCLUDES NATEGLINED AND WHEN AT LEAST ANOTHER ANTI-DIABETIC COMPOUND USED FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR OF A DISEASE OR CONDITION ASSOCIATED WITH DIBETES | |
| AR056055A1 (en) | CRYSTALLINE AND HYDRATIC COMPLEXES OF 1-CHLORINE-4- (BETA-D-GLUCOPIRANOS-1-IL) -2- (4-ETINIL-BENCIL) -BENZENE | |
| BR0213079A (en) | Dosage form for the treatment of diabetes mellitus | |
| WO1999040904A3 (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia | |
| PT1173197E (en) | METABOLIC INTERVENTION WITH GLP-1, TO IMPROVE THE FUNCTION OF ISCHEMIC AND REPERFUNDED TISSUE | |
| AR059006A1 (en) | COMPOSITIONS OF AN ANTI-CONVULSIVE AND METHODS TO USE THEM TO REVERT THE WEIGHT INCREASE | |
| BR0207726A (en) | Pharmaceutical Salts | |
| CO6331425A2 (en) | COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA | |
| UA84420C2 (en) | 1,2,4-oxadiazole benzoic acid compounds, pharmaceutical composition (variants) and their use for treating a disease ameliorated by modulation of premature translation termination or nonsense-mediated mrna decay | |
| CR7718A (en) | NEW DERIVATIVES OF THIOPHEN GLYCOSIDE, METHODS FOR THE PREPARATION OF THE SAME, MEDICINES THAT INCLUDE SUCH COMPOUNDS, AND ITS USE | |
| CL2011001735A1 (en) | Pharmaceutical composition comprising: a) the sglt2 inhibitor 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) -benzyl] -benzene, b ) dppiv linagliptin inhibitor and c) a third antidiabetic agent that is metformin hydrochloride; and its use to treat type 2 diabetes mellitus. | |
| MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
| BRPI0414428A (en) | pharmaceutical compositions | |
| AR039164A1 (en) | VENLAFAXINE SALTS OF LOW WATER SOLUBILITY | |
| SV2002000969A (en) | RECONSTITUABLE PARENTERAL COMPOSITION | |
| AR109263A2 (en) | COMPOSITION INCLUDING MOXIDECTINE | |
| AR023966A1 (en) | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF PARKINSON'S DISEASE AND THE CONCOMITING SYMPTOMS OF THE SAME, AND THE USE OF A DUAL ADENOSINE A1 A2A RECEIVER UNANTAGONIST TO PREPARE SUCH COMPOSITION | |
| GT200600163A (en) | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
| CL2007003643A1 (en) | PHARMACEUTICAL COMPOSITION OF AZIMILIDINE THAT INCLUDES 0.5% TO APPROXIMATELY 2.5% (W / W) OF WATER; AND USE FOR THE TREATMENT OF CARDIAC ARRITMIAS. | |
| CO5190674A1 (en) | TREATMENT OF NEUROTIC DISORDERS NEUROTIC DISORDERS | |
| UY25798A1 (en) | PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE INCLUDING A THIAZOLIDINADIONIC INSULIN SENSITIZER. | |
| ES2129448T3 (en) | USE OF 2- (2-NITRO-4-TRIFLUOROMETILBENZOIL) -1,3-CYCLLOHEXANODIONA IN THE TREATMENT OF THYROSINEMIA AND PHARMACEUTICAL COMPOSITIONS. | |
| AR039895A1 (en) | COMPOSITION THAT INCLUDES A VITAMIN, A METAL SALT AND AN INSULIN OR A HORMONE OF THE GROWTH AND USE OF SUCH COMPONENTS TO PREPARE IT | |
| EP1550442A4 (en) | Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20110715 |